Efficacy of Canagliflozin as an Add-on to Triple Drug Treatment With Glimepiride, Metformin and Teneligliptin

Abstract

BACKGROUNDCanagliflozin is a well-tolerated sodium-glucose transporter 2 inhibitor, with remarkable efficacy in providing glycaemic control in patients with type 2 diabetes mellitus (T2DM). However, limited evidence is available from national and international studies on the efficacy of the drug as an add-on to triple drug treatment for T2DM. The present study was aimed to evaluate the efficacy of canagliflozin (100 mg) as an add-on therapy in T2DM patients with inadequate disease control to triple drug treatment with glimepiride, metformin and teneligliptin.